NCL ICS Medicines Optimisation Governance Structure
The NCL Integrated Medicines Optimisation Committee (NCL IMOC) ensures oversight, leadership, assurance and strategy around medicines optimisation. Medicines optimisation (MO) involves ensuring consistent access to safe, effective and best-value medicines for patients.
The NCL ICS MO governance framework is outlined below (figure 1):
Figure 1: NCL ICS Medicines Optimisation Governance Structure
IMOC delegates clinical governance responsibilities to three groups:
- Medicines Finance and Value Group (MFVG)
- Medicines Clinical Reference Group (mCRG)
- NCL Joint Formulary Committee (JFC)
Groups 1 and 2 also have delegated financial responsibilities. The Pharmacy Leaders Forum (PLF) provides pharmacy strategic leadership; to support the ICS Chief pharmacist and IMOC on pharmacy and medicines optimisation workstreams and opportunities.
The aims of these four main groups are outlined in Table 1. They are responsible for identifying pharmacy and medicines optimisation priorities for the system and several sub-groups are in place to support delivery, as shown in Figure 1.
Table 1 – Medicines Optimisation Delegated Responsibility
